Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Industry, Sector and Symbol
Industry Miscellaneous plastics products
Sub-IndustryN/A
SectorConsumer Staples
Phone617-583-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$940,000.00
Profitability
Miscellaneous
Employees20
OptionableNot Optionable
Yield10 Bioscience (NASDAQ:YTEN) Frequently Asked Questions
What is Yield10 Bioscience's stock symbol?
Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."
When did Yield10 Bioscience's stock split? How did Yield10 Bioscience's stock split work?
Shares of Yield10 Bioscience reverse split on the morning of Tuesday, May 30th 2017. The 1-10 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 10 shares after the split.
How were Yield10 Bioscience's earnings last quarter?
Yield10 Bioscience Inc (NASDAQ:YTEN) announced its quarterly earnings data on Thursday, August, 9th. The specialty chemicals company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.03. The specialty chemicals company earned $0.29 million during the quarter. Yield10 Bioscience had a negative net margin of 1,878.48% and a negative return on equity of 95.70%. View Yield10 Bioscience's Earnings History.
When is Yield10 Bioscience's next earnings date?
What price target have analysts set for YTEN?
2 analysts have issued 1 year price targets for Yield10 Bioscience's stock. Their predictions range from $5.00 to $7.00. On average, they expect Yield10 Bioscience's stock price to reach $6.00 in the next year. This suggests a possible upside of 466.0% from the stock's current price. View Analyst Price Targets for Yield10 Bioscience.
What is the consensus analysts' recommendation for Yield10 Bioscience?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Yield10 Bioscience.
What are Wall Street analysts saying about Yield10 Bioscience stock?
Here are some recent quotes from research analysts about Yield10 Bioscience stock:
- 1. National Securities analysts commented, " Punching Above Its Weight Class. Yield10 represents a $10 million market cap company with technology that we believe can stand up to that of the largest names in agriculture.
Disruptive Technology. Growers are all about maximizing yield, and for decades yield enhancement technologies have been focused combatting invasive weeds and pests or by more effectively utilizing inputs. Alternatively, Yield10 has shown the ability in trials to increase yields by improving the photosynthetic process, which could fundamentally alter the yield equation.
Look Past The Chart. Long a segment of bio-plastic producer Metabolix, Yield10 stands alone as of 2017 following a spinoff of the bio-plastic division. As such, the historic price chart is not indicative of the performance of Yield10.
Commercial Relationships In Early Stages. Since late 2017, two research license agreements have been reached with Monsanto and Forage Genetics International, major players in the soybean and sorghum markets, respectively. While these are research agreements for now, we believe these announcements validate Yield10’s technology and represent the kind of relationships that could generate commercial revenue.
High Ceiling Value. Between the value of the IP portfolio in the near term, and the potential value provided by commercial revenue streams, we believe shares of Yield10 could prove to be materially undervalued at current levels. Should commercialization agreements materialize, we believe our twelve month price target could prove to be conservative." (1/23/2019)
- 2. Maxim Group analysts commented, "Today before market open, YTEN announced it granted a research license to Forage Genetics to evaluate novel yield traits in sorghum. Forage Genetics, a subsidiary of Land O’Lakes (private) devoted to seed technologies, will evaluate five novel traits within its sorghum development program to attempt to improve biomass yields. We view the research license as a long term positive, as sorghum is a leading North American export; additionally, China imports ~96% of sorghum from the U.S. We reiterate our Buy rating and $7 Price Target." (9/21/2018)
Has Yield10 Bioscience been receiving favorable news coverage?
Media stories about YTEN stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Yield10 Bioscience earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned headlines about the specialty chemicals company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Yield10 Bioscience's key competitors?
Some companies that are related to Yield10 Bioscience include DavidsTea (DTEA), Lifeway Foods (LWAY), Coffee (JVA), Amira Nature Foods (ANFI), Farmmi (FAMI), Willamette Valley Vineyards (WVVI), Ocean Bio-Chem (OBCI), Big Rock Brewery (BRBMF), Renmin Tianli Group (ABAC), Mamamancini's (MMMB), Future Fintech Group (FTFT), PwrCor (PWCO), GLG Life Tech (GLGLF), China New Borun (BORN) and Golfgear International (MCHA).
Who are Yield10 Bioscience's key executives?
Yield10 Bioscience's management team includes the folowing people:
- Dr. Oliver P. Peoples, Co-Founder, Pres, CEO & Director (Age 61)
- Dr. Anthony J. Sinskey, Co-Founder & Director (Age 79)
- Dr. Kristi Snell, VP of Research & Chief Science Officer (Age 51)
- Ms. Lynne H. Brum, VP of Planning & Communications and Sec. (Age 55)
- Mr. Charles B. Haaser, VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
How do I buy shares of Yield10 Bioscience?
Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Yield10 Bioscience's stock price today?
One share of YTEN stock can currently be purchased for approximately $1.06.
How big of a company is Yield10 Bioscience?
Yield10 Bioscience has a market capitalization of $10.63 million and generates $940,000.00 in revenue each year. The specialty chemicals company earns $-9,390,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Yield10 Bioscience employs 20 workers across the globe.
What is Yield10 Bioscience's official website?
How can I contact Yield10 Bioscience?
Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at 617-583-1700 or via email at [email protected]
MarketBeat Community Rating for Yield10 Bioscience (NASDAQ YTEN)
MarketBeat's community ratings are surveys of what our community members think about Yield10 Bioscience and other stocks. Vote "Outperform" if you believe YTEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YTEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
